MedMarket Diligence has released a report on the worldwide status of development and market for micro- and nanomedicine. The report for May 2006, number T625, identifies the technological, market, regulatory and other aspects a company must consider in commercializing its products. The report also details current activities and the status of product development at more than 100 companies active in nanotech and MEMS development.
MedMarket Diligence publishes the MedMarkets newsletter, which provides a monthly analysis of the market implications of new medical technologies along with reports on technology markets.
Currently established MEMS applications include pacemakers, glucose monitoring, biochips (genechips), OTC tests, insulin pumps, nebulizers, needleless injectors, hearing aids, activity monitors, blood pressure, medical flow sensors and drug delivery systems, the company said.
In nanomedicine, current applications include cancer chemotherapy, a new generation of drug delivery systems, wound dressings that exploit the antimicrobial properties of nanocrystalline silver and others. As of May 2006, around 150 of the largest companies in the world had nanotechnology research projects or product development plans, but that number may rise to around 300 over the next two or three years, the company said.
The report details may be found at http://www.mediligence.com/rpt-t625.htm (http://www.mediligence.com/rpt-t625.htm).
